Boston Scientific Corp (NYSE:BSX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $156.5 billion, saw its Executive Vice President and Group President of Cardiology, Joseph Michael Fitzgerald, recently engage in several stock transactions, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro analysis, the stock is currently trading near its 52-week high of $107.17.
On December 3, 2024, Fitzgerald purchased 50 shares of Boston Scientific common stock at a price of $90.29 per share, totaling approximately $4,514. Just a week later, on December 10, 2024, he sold 20 shares at a price of $89.97 per share, resulting in a total sale amount of $1,799.
Additionally, on February 11, 2025, Fitzgerald acquired 31,680 shares at no cost, as part of a performance share unit award under the company’s Total (EPA:TTEF) Shareholder Return Performance Share Program. This award was contingent on the company’s performance relative to the S&P 500 Health Care Index over a three-year period, concluding on December 31, 2024.
On the same day, Fitzgerald also disposed of 14,447 shares at a price of $105.98 per share, for a total transaction value of approximately $1,531,093. This transaction was related to the satisfaction of tax obligations.
Fitzgerald’s transactions were conducted through direct ownership, with no involvement of equity swaps. Notably, a prior transaction dated December 10, 2024, was executed by a broker without Fitzgerald’s knowledge.
In other recent news, Boston Scientific Corporation announced the departure of board member Charles J. Dockendorff, who will not seek re-election at the upcoming 2025 Annual Meeting of Stockholders. The company has not yet indicated any potential candidates to fill the vacancy. Meanwhile, financial analysts from Stifel, RBC Capital, Truist Securities, and Mizuho (NYSE:MFG) Securities have all recently upgraded their price targets for Boston Scientific. Stifel increased its target from $115 to $120, maintaining a Buy rating, citing confidence in the company’s future financial performance. RBC Capital raised its price target to $116, emphasizing the company’s robust fourth-quarter performance and strong initial guide for 2025. Truist Securities lifted its target to $120, highlighting the company’s strong product pipeline and favorable markets. Lastly, Mizuho Securities raised its target to $130, noting the strong market adoption of Boston Scientific’s FARAPULSE product and the potential for strategic mergers and acquisitions. These are among the recent developments for Boston Scientific.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.